Core Viewpoint - Vitiligo is a complex autoimmune disease with no clear treatment options, affecting approximately 30 million people in China, with a significant portion of patients experiencing anxiety and depression due to the condition [3][4]. Treatment Landscape - Current treatment methods for vitiligo in China are limited, primarily involving topical corticosteroids and calcineurin inhibitors, which only suppress immune responses and do not promote repigmentation or prevent relapse [4]. - The FDA has approved the JAK inhibitor ruxolitinib cream for the treatment of non-segmental vitiligo in patients aged 12 and older, but it is not yet available in China and cannot be used for children under 12 [5]. Market Potential - The market for innovative vitiligo treatments in China is projected to reach 120 billion to 259 billion yuan under conservative to optimistic scenarios, indicating a significant opportunity for new products [6]. - The current pipeline for vitiligo treatments is not overly crowded, suggesting that successful new therapies that balance safety and efficacy could quickly gain market share due to unmet clinical needs [6]. Research and Development - Several domestic pharmaceutical companies are actively developing new treatments for vitiligo, including new JAK inhibitors and innovative approaches like the CKBA ointment being developed by TianKang, which targets T-cell fatty acid metabolism [5][6]. - TianKang has reported promising results from the Phase II clinical trials of CKBA ointment and is advancing to Phase III trials while seeking breakthrough therapy designation from the National Medical Products Administration [5].
中国患者数量过千万，白癜风的治疗困局在哪